Is COO a Buy or a Sell? The Bull and Bear Case (2026)

Last updated October 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for The Cooper Companies (COO) rests on Myopia management and premium lens mix: CooperVision's growth comes less from unit volume than from moving wearers up the price ladder into daily silicone hydrogel, torics and multifocals. The bear case rests on demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S. Analysts covering it publish targets from $58.00 to $75.00 against a $57.94 price, so even the professionals disagree by 26% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

The Cooper Companies, headquartered in San Ramon, California and employing roughly ~15,000 people, has run on the same two-segment structure for years. CooperVision, about two thirds of revenue at ~$717.0M in the July 2026 quarter, makes soft contact lenses: daily disposables in silicone hydrogel, torics for astigmatism, multifocals for presbyopia, and MiSight 1 day, the only daily disposable lens with FDA approval to slow the progression of myopia in children. CooperSurgical, the other third at ~$349.2M, splits into fertility (IVF consumables, embryo culture media, cryostorage and genetic testing sold to fertility clinics) and an office and surgical line of devices sold into OB/GYN practices. The fiscal year ends October 31, so results labelled fiscal 2026 largely cover calendar 2026. The investment picture in October 2026 is unusually two-sided. Trailing revenue of ~$4.24B is barely growing (the July quarter was up ~0.6% and missed consensus by about 3%), yet adjusted EPS of $1.15 beat the $1.11 estimate and adjusted operating margin edged up to ~26.3%. The shares sit near ~$58, down ~29% year to date and ~19% over twelve months, against a 52-week range of roughly ~$51 to ~$90. Several things pulled them down: a June guidance trim driven by consumer weakness in Japan and China, a ~$271.6M net pre-tax charge to settle claims from the December 2023 embryo culture media recall at CooperSurgical, U.S. channel inventory reductions that left CooperVision flat in the July quarter, and a September guidance cut to ~$4.229B to ~$4.252B of fiscal 2026 revenue and ~$4.51 to ~$4.55 of adjusted EPS. The stock also fell on the conclusion of the strategic review begun in December 2025; no sale of CooperSurgical has been announced. In mid-September JANA Partners went public asking Cooper to replace CEO Albert White and the board chair and to explore selling all or part of both segments, with a proxy fight possible ahead of a January nomination deadline. Several directors, including Kurzius, Rosebrough and the recently appointed Paul Keel, bought shares in the open market in early October. Debt was ~$2.54B against ~$155M of cash at the end of July.

The bull case: what would have to be true for $75.00

The most optimistic published target on COO is $75.00, +29.4% from the $57.94 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Myopia management and premium lens mix

CooperVision's growth comes less from unit volume than from moving wearers up the price ladder into daily silicone hydrogel, torics and multifocals. MiSight 1 day sits at the top of that ladder, and Cooper has been extending it into Japan, Australia and New Zealand, markets where childhood myopia rates are among the highest in the world (as many as ~77% of Japanese elementary school children are estimated to be myopic). Pediatric myopia control is a category Cooper largely created, and it carries better pricing and stickier patient relationships than commodity spheres.

2. Activist pressure and a possible breakup

The strategic review announced on December 4, 2025 put the whole portfolio on the table, and management said through the summer that it was in advanced discussions with parties interested in CooperSurgical, with sell-side estimates of the unit clustering near ~$4.1B. The review has since concluded without an announced sale, and the shares fell on that news. JANA Partners responded in mid-September 2026 by asking Cooper to explore selling all or part of CooperVision and CooperSurgical and to replace the CEO and board chair, citing inventory management and capital allocation. A separation would still leave a pure-play contact lens company with higher margins and a simpler story, but the path there is now a governance fight rather than a negotiated sale.

3. Fertility volumes inside CooperSurgical

Fertility is the fastest-growing line Cooper owns over the past year, though growth slowed to ~3% in the July quarter (~$141.2M) from ~13% in the April quarter. Later family formation, wider employer IVF coverage and clinic consolidation all push volumes in the same direction, and Cooper supplies the consumables, culture media, cryostorage and genetic testing that clinics buy repeatedly. Whether shareholders keep that exposure depends on how the activist campaign and any future divestiture play out.

4. Cash generation, buybacks and deleveraging

Adjusted gross margin of ~66.7% and adjusted operating margin of ~26.3% in the July quarter mean the underlying business still converts revenue into cash in a soft demand year; trailing free cash flow is about ~$543M and operating cash flow about ~$1.03B. Management reaffirmed a goal of more than ~$2.2B of cumulative free cash flow across fiscal 2026 to 2028. Heavy manufacturing capex for lens capacity is a real but finite call on cash, and buybacks plus cutting the ~$2.54B debt load remain the stated priorities.

The bear case: what would have to be true for $58.00

The most pessimistic published target is $58.00, +0.1% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks The Cooper Companies is worth if the risks below bite instead of the drivers above.

Demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S. channel inventory reductions left CooperVision flat in the July quarter, and full-year guidance was cut twice, in June and again in September, with tariff costs and currency layered on top. The December 2023 recall of three lots of LifeGlobal embryo culture media at CooperSurgical produced more than 140 lawsuits and over 1,500 claimants, and the ~$271.6M net charge booked to resolve substantially all of those claims turned the April quarter into a GAAP loss, with some residual exposure remaining. GAAP results now swing the other way too: a ~$307.2M discrete tax benefit from a U.K. tax examination lifted July-quarter GAAP EPS to $2.24, which flatters the trailing P/E. JANA's campaign could bring a proxy contest, a leadership change or a forced sale, any of which carries execution risk. CooperVision also competes against Johnson and Johnson, Alcon and Bausch and Lomb, all of which have deeper balance sheets and can price aggressively when the market slows.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding COO already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on COO

15 analysts cover COO, with an average target of $65.80 (+13.6% against $57.94) and a split of 5 buy, 12 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the COO forecast and price target page.

How is COO valued? (as of October 2026)

Price

$57.94

Market cap

$11.02B

P/E (TTM)

19.91

Forward P/E

12.35

Price / book

1.32

Beta

0.82

52-week range

$51.01 to $89.83

Snapshot for COO as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$4.24B; July quarter up ~0.6%
Fiscal 2026 revenue guidance (September): ~$4.229B to ~$4.252B
Fiscal 2026 adjusted EPS guidance: ~$4.51 to ~$4.55
Forward P/E: ~12x at ~$58 per share
GAAP P/E (TTM): ~20x on GAAP EPS of ~$2.91 (includes tax benefit)
Margins (TTM): ~66% gross, ~21% operating
Market cap: ~$11B
Total debt (July 31, 2026): ~$2.54B, ~$155M cash

GAAP and non-GAAP still diverge sharply, now in both directions: the trailing GAAP figure absorbs the ~$271.6M litigation charge and years of acquisition amortization but also a ~$307.2M U.K. tax benefit. On adjusted EPS guidance of ~$4.51 to ~$4.55, the shares at ~$58 trade near 12-13x, well below the multiple Cooper carried through most of the last decade, and 15 analysts hold a hold rating with a mean target near ~$65.80. The fiscal year closes October 31, and fourth-quarter guidance is ~$1.057B to ~$1.080B of revenue and ~$1.05 to ~$1.09 of adjusted EPS.

How do you decide if COO is a buy?

Rather than asking whether COO is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the bull case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold COO indirectly through an index or sector ETF before adding more.

What would change your mind on COO

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

Bull case breaks if: Myopia management and premium lens mix stalls in the reported numbers rather than in the narrative around them.
Bear case breaks if: demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S fails to materialise over several reporting periods while the drivers keep compounding.
Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the COO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about COO against your real portfolio and see your actual exposure before deciding.

Investing in The Cooper Companies with AI

Connect the broker you already use and ask Walnut's AI how COO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does COO fit me?

FAQ

Is COO a good stock to buy right now?

That depends on which case you find more convincing, and both are on this page. The bull case rests on Myopia management and premium lens mix, with revenue (ttm) at ~$4.24B; July quarter up ~0.6%. The bear case rests on demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S. Analysts covering it are spread from $58.00 to $75.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Should I sell COO?

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $58.00, +0.1% from the $57.94 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

What is the bull case for COO?

Myopia management and premium lens mix. CooperVision's growth comes less from unit volume than from moving wearers up the price ladder into daily silicone hydrogel, torics and multifocals. The most optimistic analyst target on COO is $75.00, +29.4% from the $57.94 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for COO?

What does The Cooper Companies do?

The Cooper Companies runs two medical device businesses: CooperVision in soft contact lenses and myopia management, and CooperSurgical in fertility and women's health.

What would have to change for COO to stop being worth holding?

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Myopia management and premium lens mix) stalling in the reported numbers rather than in the narrative, the risk above (demand is the immediate problem: consumer weakness in Japan and China pushed CooperVision revenue in Asia-Pacific down ~6% earlier in the year, U.S) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does The Cooper Companies actually do?

It runs two medical device businesses. CooperVision, roughly two thirds of revenue, makes soft contact lenses including dailies, torics, multifocals and the MiSight myopia control lens for children. CooperSurgical, the other third, sells fertility products such as IVF consumables and culture media plus devices used in OB/GYN offices and surgery.

Has COO done a stock split? The price looks low for a company this size.

Yes. Cooper completed a 4-for-1 stock split effective February 16, 2024, with split-adjusted trading beginning February 20, 2024. The ~$58 quote of October 2026 is post-split, equivalent to roughly ~$231 on the old share count. Any per-share figure taken from before February 2024 needs dividing by four before comparing.

How big is each segment?

In the quarter ended July 31, 2026, CooperVision produced ~$717.0M of revenue (flat year over year, held back by U.S. channel inventory reductions) and CooperSurgical ~$349.2M (up ~3% organically). Within CooperSurgical, fertility was ~$141.2M and up ~3%. In the April quarter the split had been ~$723.5M and ~$358.0M.

Walnut is informational, not investment advice, and gives no verdict on COO. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.